Catumaxomab
Catumaxomab
Catumaxomab (pronounced: ka-too-max-o-mab) is a monoclonal antibody used for the treatment of malignant ascites. It is the first drug to be approved that functions as a trifunctional antibody, meaning it can bind to three different types of cells: cancer cells, T cells, and accessory cells.
Etymology
The name "Catumaxomab" is derived from the Latin word "catum", meaning "battle", and "maxomab", a common suffix for monoclonal antibodies. This reflects the drug's function as a "battle" against cancer cells.
Mechanism of Action
Catumaxomab works by binding to the EpCAM antigen on the surface of cancer cells and the CD3 antigen on T cells. This brings the T cells into close proximity with the cancer cells, allowing them to destroy the cancer cells more effectively. The Fc region of catumaxomab also binds to accessory cells, which provide additional support to the T cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Ascites: A condition in which fluid collects in the abdomen, often due to advanced cancer.
- EpCAM: An antigen that is often overexpressed on the surface of cancer cells.
- T cells: A type of white blood cell that is an essential part of the immune system.
- Accessory cells: Cells that assist in the immune response, such as dendritic cells and macrophages.
See Also
External links
- Medical encyclopedia article on Catumaxomab
- Wikipedia's article - Catumaxomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski